-
Mashup Score: 45Urgent action needed to achieve viral hepatitis elimination - 15 day(s) ago
The headline figures from WHO’s 2024 Global Hepatitis Report, released at the World Hepatitis Summit in Lisbon, Portugal, on April 9, make for stark reading. 1·3 million people died from viral hepatitis in 2022: the same number as killed by tuberculosis, second only to COVID-19 as the leading communicable cause of death, and an increase on the 2019 estimate of 1·1 million. There were 1·2 million new hepatitis B infections and almost 1 million new hepatitis C infections in 2022—marginally lower than 2019 estimates, but not substantially so.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 45Urgent action needed to achieve viral hepatitis elimination - 15 day(s) ago
The headline figures from WHO’s 2024 Global Hepatitis Report, released at the World Hepatitis Summit in Lisbon, Portugal, on April 9, make for stark reading. 1·3 million people died from viral hepatitis in 2022: the same number as killed by tuberculosis, second only to COVID-19 as the leading communicable cause of death, and an increase on the 2019 estimate of 1·1 million. There were 1·2 million new hepatitis B infections and almost 1 million new hepatitis C infections in 2022—marginally lower than 2019 estimates, but not substantially so.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 4Loss of Anti-TNF Treatment Response Common in Crohn's Disease - 16 day(s) ago
Study identified factors and strategies for maintaining response
Source: www.medpagetoday.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 19Top-Down Therapy Proves Its Worth in Crohn’s Disease - 17 day(s) ago
Adults newly diagnosed with active Crohn’s disease benefit from immediate treatment with advanced therapies, according to research.
Source: www.gastroendonews.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 4What’s the Best Way to Treat I.B.S.? - 20 day(s) ago
A new study suggests that certain dietary changes may be more effective than medication.
Source: www.nytimes.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 18
Both a special diet that excludes “FODMAP” compounds and a low-carb high-fibre diet were effective
Source: www.newscientist.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 53
Two 4-week dietary interventions and optimised medical treatment reduced the severity of IBS symptoms, with a larger effect size in the diet groups. Dietary interventions might be considered as an initial treatment for patients with IBS. Research is needed to enable personalised treatment strategies.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 39
Portal hypertension represents the primary non-neoplastic complication of liver cirrhosis and has life-threatening consequences, such as oesophageal variceal bleeding, ascites, and hepatic encephalopathy. Portal hypertension occurs due to increased resistance of the cirrhotic liver vasculature to portal blood flow and is further aggravated by the hyperdynamic circulatory syndrome. Existing knowledge indicates that the profibrogenic phenotype acquired by sinusoidal cells is the initial factor leading to increased hepatic vascular tone and fibrosis, which cause increased vascular resistance and portal hypertension.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0
Although the past 10 years have brought a wave of novel medications and mechanisms to the management of Crohn’s disease and inflammatory bowel disease (IBD), anti-TNF therapy remains a cornerstone of treatment, and due to the development of biosimilar agents, remains highly cost effective. The recently published PROFILE trial has highlighted that impressively high 1-year remission rates can be obtained when anti-TNF therapies are introduced very early in disease management.1 However, a drawback of adopting earlier introduction of biologics is a drive towards increased use of advanced therapies in Crohn’s disease, with an impact on cost for payers.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 51
Only around a third of patients with active luminal Crohn’s disease treated with an anti-TNF drug were in remission at the end of 3 years of treatment. Low drug concentrations at the end of the induction period predict loss of response by year 3 of treatment, suggesting higher drug concentrations during the first year of treatment, particularly during induction, might lead to better long-term outcomes. Anti-drug antibodies associated with undetectable drug concentrations of infliximab, but not adalimumab, can be predicted by carriage of HLA-DQA1*05 and mitigated by concomitant immunomodulator use for both drugs.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
New Editorial - Urgent action needed to achieve viral hepatitis elimination https://t.co/ckHNlGFXyu #NoHep #LiverTwitter https://t.co/YR9zquvtlf